Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,662 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B.
Shapiro AD, Kulkarni R, Ragni MV, Chambost H, Mahlangu J, Oldenburg J, Nolan B, Ozelo MC, Foster MC, Willemze A, Barnowski C, Jain N, Winding B, Dumont J, Lethagen S, Barnes C, Pasi KJ. Shapiro AD, et al. Among authors: jain n. Blood Adv. 2023 Jul 11;7(13):3049-3057. doi: 10.1182/bloodadvances.2022009230. Blood Adv. 2023. PMID: 36848635 Free PMC article.
Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis.
Carcao M, Shapiro A, Staber JM, Hwang N, Druzgal C, Lieuw K, Belletrutti M, Thornburg CD, Ahuja SP, Morales-Arias J, Dumont J, Miyasato G, Tsao E, Jain N, Pipe SW. Carcao M, et al. Among authors: jain n. Haemophilia. 2018 Mar;24(2):245-252. doi: 10.1111/hae.13413. Epub 2018 Feb 13. Haemophilia. 2018. PMID: 29436077 Free article.
RE: Reyes A, Révil C, Niggli M, et al. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Curr Med Res Opin. 2019;35(12):2079-2087.
Jain N, Lethagen S. Jain N, et al. Curr Med Res Opin. 2020 Jul;36(7):1125-1127. doi: 10.1080/03007995.2020.1744549. Epub 2020 Apr 7. Curr Med Res Opin. 2020. PMID: 32253943 No abstract available.
Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years.
Shapiro A, Chaudhury A, Wang M, Escobar M, Tsao E, Barnowski C, Feng J, Jain N, Quon DV. Shapiro A, et al. Among authors: jain n. Haemophilia. 2020 Nov;26(6):975-983. doi: 10.1111/hae.14152. Epub 2020 Oct 4. Haemophilia. 2020. PMID: 33012060 Free PMC article.
Real-world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A follow-up retrospective analysis.
Carcao M, Shapiro A, Hwang N, Pipe S, Ahuja S, Lieuw K, Staber JM, Belletrutti M, Sun HL, Ding H, Wang M, Price V, Steele M, Tsao E, Feng J, Al-Khateeb Z, Dumont J, Jain N. Carcao M, et al. Among authors: jain n. Haemophilia. 2021 Jan;27(1):19-25. doi: 10.1111/hae.14192. Epub 2020 Nov 18. Haemophilia. 2021. PMID: 33210397 Free PMC article. No abstract available.
Recent advances in therapeutic options for rare hemostatic disorders: selected poster extracts of recent research in hemophilia A, congenital hemophilia with inhibitors, von Willebrand disease, and thrombotic thrombocytopenic purpura presented at the 29th congress of the International Society on Thrombosis and Haemostasis (ISTH 2021, Jul 17-21; virtual congress).
Jain N, Oldenburg J, Ozelo MC, Sun SX, Tang L, Tzivelekis S. Jain N, et al. Expert Rev Hematol. 2022 May;15(sup1):1-18. doi: 10.1080/17474086.2022.2074395. Epub 2022 Jun 24. Expert Rev Hematol. 2022. PMID: 35748691
3,662 results